Muscle relaxants as alternative analgesics in the treatment of nonspecific back pain
https://doi.org/10.14412/2074-2711-2017-2-89-94
Abstract
Only 50% of patients treated for back pain achieve effective relief. This is to some extent due to physicians' insufficient knowledge about the therapeutic strategies recommended in most expert guidelines. The widespread administration of muscle relaxants is traditional in clinical practice because of their high efficacy and long-term experience with their use in different categories of patients. Muscle relaxants are presented in the majority of the current clinical guidelines; their use is indicated when simple analgesics (paracetamol), nonsteroidal anti-inflammatory drugs, or combined and opioid analgesics do not provide sufficient analgesia. Muscle relaxants are characterized by a considerable analgesic effect in the short-term treatment of acute low back pain. It is noted that there is a need for a more thorough analysis of the therapeutic effects of muscle relaxants in patients with common pain syndromes.
About the Author
G. R. Tabeeva
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow
Russian Federation
Russian Federation
Department of Nervous System Diseases and Neurosurgery
11, Rossolimo St., Moscow 119021
References
1. Van Tulder M, Koes B, Bombardier C. Low back pain. Best Pract Res Clin Rheumatol. 2002 Dec;16(5):761-75.
2. Парфенов ВА, Герасимова ОН. Ведение пациентов с болью в спине в амбулаторной практике. Неврология, нейропсихиатрия, психосоматика. 2010;2(4):65-71. [Parfenov VA, Gerasimova ON. Management of patients with back pain in outpatient practice. Nevrologiya, neiщropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2010;2(4): 65-71. (In Russ.)] . doi: 10.14412/2074-2711- 2010-120
3. Woolf AD, Pleger B. Burden of major musculoskeletal conditions. Bull World Health Organ. 2003;81(9):646-56. Epub 2003 Nov 14.
4. Nyiendo J, Haas M, Goldberg B, Sexton G. Pain, disability, and satisfaction outcomes and predictors of outcomes: A practice-based study of chronic low back pain patients attending primary care and chiropractic physicians. J Manipulative Physiol Ther. 2001 Sep;24(7): 433-9.
5. Werner EL, Ihlebaek C, Skouen JS, Laerum E. Beliefs about low back pain in the Norwegian general population: Are they related to pain experiences and health professionals? Spine (Phila Pa 1976). 2005 Aug 1;30(15):1770-6.
6. Парфенов ВА, Исайкин АИ. Боль в нижней части спины: мифы и реальность. Моск- ва: ИМА-ПРЕСС; 2016. 104 с. [Parfenov VA, Isaikin AI. Bol' v nizhnei chasti spiny: mify i real'nost' [Low back pain: myths and reality]. Moscow: IMA-PRESS; 2016. 104 p.]
7. Van Tulder M, Becker A, Bekkering T, et al; COST B13 Working Group on Guidelines for the Management of Acute Low Back Pain in Primary Care. Chapter 3. European guidelines for the management of acute nonspecific low back pain in primary care. Eur Spine J. 2006 Mar;15 Suppl 2:S169-91.
8. Koes BW, van Tulder M, Lin CW, et al. An updated overview of clinical guidelines for the management of non-specific low back pain in primary care. Eur Spine J. 2010 Dec;19(12): 2075-94. doi: 10.1007/s00586-010-1502-y. Epub 2010 Jul 3.
9. Rossignol M, Abenhaim L, Bonvalot Y, et al. Should the gap be filled between guidelines and actual practice for management of low back pain in primary care? The Quebec experience. Spine (Phila Pa 1976). 1996 Dec 15;21(24): 2893-8.
10. NA Scott, C Moga, C Harstall. Managing low back pain in the primary care setting: The know-do gap. Pain Res Manag. 2010 Nov-Dec; 15(6):392-400.
11. Bishop PB, Wing PC. Compliance with clinical practice guidelines in family physicians managing worker's compensation board patients with acute lower back pain. Spine J. 2003 Nov-Dec;3(6):442-50.
12. Waddell G, McIntosh A, Hutchinson A, et al. Low back pain evidence review Royal College of General Practitioners. www.chiro.org/ LINKS/GUIDELINES/FULL/Royal_College /index.html
13. van Tulder MW, Touray T, Furlan AD, et al; Cochrane Back Review Group. Muscle relaxants for nonspecific low back pain: A systematic review within the framework of the cochrane collaboration. Spine (Phila Pa 1976). 2003 Sep 1; 28(17):1978-92.
14. See S, Ginzburg R. Choosing a Skeletal Muscle Relaxant. Am Fam Physician. 2008 Aug 1; 78(3):365-70.
15. Luo X, Pietrobon R, Curtis LH, Hey LA. Prescription of nonsteroidal anti – in ammatory drugs and muscle relaxants for back pain in the United States. Spine (Phila Pa 1976). 2004 Dec 1; 29(23):E531-7.
16. Van Tulder MW, Touray T, Furlan AD, et al. Muscle relaxants for non-specific low back pain. Cochrane Database Syst Rev. 2003;(2): CD004252.
17. Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage. 2004 Aug;28(2):140-75.
18. Shaheed CA, Maher CG, Williams KA, McLachlan AJ. Efficacy and tolerability of muscle relaxants for low back pain: Systematic review and meta-analysis. Eur J Pain. 2017 Feb;21(2):228-237. doi: 10.1002/ejp.907. Epub 2016 Jun 22.
19. Beebe FA, Barkin RL, Barkin S. A clinical and pharmacologic review of skeletal muscle relaxants for musculoskeletal conditions. Am J Ther. 2005 Mar–Apr;12(2):151-71.
20. Pratzel HG, Alken RG, Ramm S. Efficacy and tolerance of repeated oral doses of tolperisone hydrochloride in the treatment of painful reflex muscle spasm: results of a prospective placebo-controlled double-blind trial. Pain. 1996 Oct;67(2-3):417-25.
21. Tekes K. Basic Aspects of the Pharmacodynamics of Tolperisone, A Widely Applicable Centrally Acting Muscle Relaxant. Open Med Chem J. 2014 Jul 11;8:17-22. doi: 10.2174/1874104501408010017. eCollection 2014.
22. Farkas S, Tarnawa I, Berzsenyi P. Effects of some centrally acting muscle relaxants on spinal root potentials: a comparative study. Neuropharmacology. 1989 Feb;28(2):161-73.
23. Kocsis P, Farkas S, Fodor L, et al. Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3): 1237-46. Epub 2005 Aug 26.
24. Sakitama K, Ozawa Y, Aoto N, et al. Pharmacological properties of NK433, a new centrally acting muscle relaxant. Eur J Pharmacol. 1995 Jan 24;273(1-2):47-56.
25. Sakaue A, Honda M, Tanabe M, Ono H. Antinociceptive effects of sodium channel-blocking agents on acute pain in mice. J Pharmacol Sci. 2004 Jun;95(2):181-8.
26. Quasthoff S, Pojer C, Mori A, et al. No blocking effects of the pentapeptide QYNAD on Na+ channel subtypes expressed in Xenopus oocytes or action potential conduction in isolated rat sural nerve. Neurosci Lett. 2003 Dec 4; 352(2):93-6.
27. Patel KS, Sachdeva PD. Centrally Mediated Anti-Hyperalgesic and Anti-Allodynic Effect of Tolperisone in Spared Nerve Injury Model of Neuropathic Pain. JPSBR. 2013;3(4):122-126.
28. Goldin AL. Diversity of mammalian voltage-gated sodium channels. Ann N Y Acad Sci. 1999 Apr 30;868:38-50.
29. Kocsis P, Gajаri D, Deli L, et al. Effect of tolperisone on the resting brain and on evoked responses, an phMRI BOLD study. Brain Res Bull. 2013 Oct;99:34-40. doi: 10.1016/j.brainresbull.2013.09.008. Epub 2013 Oct 4.
30. Quasthoff S, Mö ckel C, Zieglgä nsberger W, Schreibmayer W. Tolperisone: a typical representative of a class of centrally acting muscle relaxants with less sedative side effects. CNS Neurosci Ther. 2008 Summer;14(2):107-19. doi: 10.1111/j.1527-3458.2008.00044.x.
31. Melka A, Tekle-Haimanot R, Lambien F. Symptomatic treatment of neurolathyrism with tolperisone HCL (Mydocalm): a randomized double blind and placebo controlled drug trial. Ethiop Med J. 1997 Apr;35(2):77-91.
32. Stamenova P, Koytchev R, Kuhn K, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke. Eur J Neurol. 2005 Jun;12(6):453-61.
33. Prabhoo R, Keny S, Prabhoo T, et al. A phase IV observational multi-centre, openlabel study on efficacy and safety of tolperisone 150 mg in patients with painful muscle spasm associated with degenerative or inflammatory diseases of the musculoskeletal system. J Assoc Physicians India. 2011 Jan;59:33-7.
34. Rao R, Panghate A, Chandanwale A, et al. Clinical comparative study: efficacy and tolerability of tolperisone and thiocol chicoside in acute low back pain and spinal muscle spasticity. Asian Spine J. 2012 Jun;6(2):115-22. doi: 10.4184/asj.2012.6.2.115. Epub 2012 May 31.
35. Скоромец АА, Гехт АБ, Галанов ДВ и др. Результаты международного фармако-эпидемиологического наблюдательного проекта по применению мидокалма для лечения болевых синдромов, сопровождающихся мышечным спазмом. Журнал неврологии и психиатрии им. С.С. Корсакова. 2015; 115(12):104-9. [Skoromets AA, Gekht AB, Galanov DV, et al. The results of the international pharmaco-epidemiological observational project on the use of midokalm for the treatment of pain accompanied by muscle spasm. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2015;115(12):104-9. (In Russ.)].
Review
For citations:
Tabeeva G.R. Muscle relaxants as alternative analgesics in the treatment of nonspecific back pain. Neurology, Neuropsychiatry, Psychosomatics. 2017;9(2):89-94. (In Russ.) https://doi.org/10.14412/2074-2711-2017-2-89-94
Views: 1432
Email this article 